Xenon Pharmaceuticals

Yahoo Finance • last month

This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough

On February 17, 2026, Driehaus Capital Management disclosed a buy of Xenon Pharmaceuticals(NASDAQ:XENE), adding 369,577 shares in an estimated $15.52 million trade based on quarterly average pricing. What happened According to an SEC fil... Full story

Yahoo Finance • last month

Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should Know

Driehaus Capital Management disclosed a significant buy of Eos Energy Enterprises(NASDAQ:EOSE) in its February 17, 2026, SEC filing, adding 7.70 million shares in an estimated $110.72 million trade based on quarterly average pricing. What... Full story

Yahoo Finance • last month

Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight

The bipolar depression market is anticipated to increase during the forecast period (2026–2036), owing to the rise in the launch of emerging therapies such as Azetukalner (Xenon Pharmaceuticals), Elunetirom (ABX-002) (Autobahn Therapeutics... Full story

Yahoo Finance • last month

Xenon Pharmaceuticals prices upsized $650M public offering at $57/share

Xenon Pharmaceuticals (XENE [https://seekingalpha.com/symbol/XENE]) announced pricing of its upsized underwritten public offering [https://seekingalpha.com/pr/20432360-xenon-pharmaceuticals-announces-pricing-of-upsized-650_0-million-public... Full story

Yahoo Finance • last month

Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering

VANCOUVER, British Columbia and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercializatio... Full story

Yahoo Finance • last month

Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026

VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercializatio... Full story

Yahoo Finance • 2 months ago

Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress

On February 13, 2026, Affinity Asset Advisors disclosed a new position in Praxis Precision Medicines(NASDAQ:PRAX), acquiring 185,000 shares in an estimated $54.53 million trade. What happened According to a SEC filing dated February 13,... Full story

Yahoo Finance • 2 months ago

Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million

On February 13, 2026, Affinity Asset Advisors disclosed a purchase of 61,500 shares of Apogee Therapeutics(NASDAQ:APGE), an estimated $3.87 million trade based on quarterly average pricing. What happened According to an SEC filing dated... Full story

Yahoo Finance • 4 months ago

Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025

Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OLE, with 38% achieving ≥1 year of seizure freedom New X-TOLE OLE data analysis supports the ability to attain and regain extended periods of... Full story

Yahoo Finance • 4 months ago

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercializatio... Full story

Yahoo Finance • 4 months ago

Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors

Key Points New York City-based Commodore Capital initiated a stake of 5.7 million shares of Terns Pharmaceuticals in the third quarter, an increase of $42.8 million in position value. The new position represents 2.1% of 13F reportable ass... Full story

Yahoo Finance • 5 months ago

Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025

Seven posters to be presented, including new X-TOLE OLE data supporting the ability to attain and regain extended periods of seizure freedom with long-term use of azetukalnerData will also highlight the impact of depression and burden of t... Full story

Yahoo Finance • 6 months ago

Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer

VANCOUVER, British Columbia and BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercializatio... Full story

Yahoo Finance • 7 months ago

Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain

VANCOUVER, British Columbia and BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercializati... Full story

Yahoo Finance • 7 months ago

Design Therapeutics Appoints Justin Gover to Board of Directors

CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of ind... Full story

Yahoo Finance • 8 months ago

Xenon targets NDA filing for azetukalner within 6 months of phase III readout while advancing late-stage neuropsychiatric programs

Earnings Call Insights: Xenon Pharmaceuticals (XENE) Q2 2025 MANAGEMENT VIEW * Ian C. Mortimer, President and CEO, highlighted that Xenon has completed patient recruitment in its pivotal X-TOLE2 Phase III clinical trial for azetukalner... Full story

Yahoo Finance • 8 months ago

Xenon Reports Second Quarter 2025 Financial Results & Business Update

– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026 – Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED in BPD recently initiated – Phase 1 he... Full story

Yahoo Finance • 8 months ago

Xenon Pharma Q2 2025 Earnings Preview

* Xenon Pharma (NASDAQ:XENE [https://seekingalpha.com/symbol/XENE]) is scheduled to announce Q2 earnings results on Friday, August 11th, after market close. The consensus EPS Estimate is -$0.99 [https://seekingalpha.com/symbol/XENE/earn... Full story

Yahoo Finance • 8 months ago

Xenon to Report Q2 2025 Financial Results on August 11, 2025

VANCOUVER, British Columbia and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing ther... Full story

Yahoo Finance • 9 months ago

H.C. Wainwright reaffirms Buy rating on Xenon Pharmaceuticals stock at $53

Investing.com - H.C. Wainwright has reiterated its Buy rating and $53.00 price target on Xenon Pharmaceuticals (NASDAQ:XENE), highlighting the company’s leadership in ion channel drug development for CNS disorders. According to Investing... Full story